Skip to main content
Fig. 3 | Journal of Experimental & Clinical Cancer Research

Fig. 3

From: Bazedoxifene as a novel GP130 inhibitor for Colon Cancer therapy

Fig. 3

Bazedoxifene inhibits STAT3, AKT and ERK phosphorylation and downregulates expression of STAT3 downstream proteins. DLD-1, HCT-15, and HCT-116 human colon cancer cells were treated with different concentrations of bazedoxifene (10~35 μM) for 24 to 48 h. The protein expression of p-STAT3Y705, p-AKTS473, p-ERK1/2T202/Y204, BCL-XL, cyclin D1, survivin, c-myc, ERK, AKT and STAT3 were detected by western blots with GAPDH as a loading control

Back to article page